Faculty

Institution

Unit

Venue

Robert M. Wilechansky

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Digestive Health Center

Division Of Hematology/Medical Oncology

Division of Gastroenterology & Hepatology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

NoneRobert M. Wilechansky is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert M. Wilechansky

Oregon Health & Science University

You can click a keyword to filter the displayed items

hepatology medicine pathology liver disease epidemiology public health gastroenterology digestive diseases liver physiology nephrology oncology liver transplantation diabetes research diabetes mellitus fatty liver disease hematology clinical transplantation laboratory medicine histopathology diabetic medicine gastrointestinal surgery acute kidney injury acute liver failure transplantation medicine fibrosis hepatotoxicity interventional endoscopy hospitalized patients type 2 covid-19 veterinary medicine virology respiratory medicine addiction medicine complementary medicine medicinal research xenotransplantation transplant infectious diseases intensive care clinical evidence clinical pathology human pathology veterinary pathology viral hepatitis alcohol abuse disease assessment disease risk assessment disease classification adverse events graft survival symptomatic treatment hepatobiliary tumors biliary cancer digestive system surgery food intolerance brain imaging neuroimaging modality translational physiology informed consent mechanisms of action system pharmacology translational pharmacology hepatorenal syndrome persistent cholestatic injury secondary sclerosing cholangitis combined tobacco use prevalent fibrosis alcohol-associated hepatitis hrs harmony consortium united states hrs-harmony consortium liver transplant rates rise worldwide duodenal hematoma arterial embolization case report

Notable Scholarly Works

Notable Federal Grants

Collaborators

106 Relationship of Healthy Diet Adherence and Incident Masld and Cirrhosis in a Pooled Analysis of Three Large Prospective Cohorts. Gastrointestinal Endoscopy (2026)

interventional endoscopypublic healthepidemiologychronic diseasesgastrointestinal endoscopydigestive endoscopygastroenterologyhepatologydigestive diseasesfood intolerancehealth sciences

Par for the Course? Comparative Effectiveness of Ppar Agonists in Pbc. Hepatology (2026)

drug metabolismapplied pharmacologyppar agonistsmedicinepharmacologymolecular pharmacologytranslational pharmacologypharmacotherapypharmacological researchsystem pharmacologyhealth sciencescomparative effectivenessmechanisms of action

Breaching the Blood–Brain Barrier: Functional Mri Changes in Covert Hepatic Encephalopathy. Hepatology (2025)

neurologycovert hepatic encephalopathyliver physiologybrain imagingfunctional imaginghepatologyneuroscienceblood–brain barrierradiologyneuroradiologyfunctional mri changesneuroimagingneuroimaging modality

Not so Sweet: Faster Liver Stiffness Progression in Masld With Type 2 Diabetes. Hepatology (2025)

diabetes caremetabolic syndromefatty liver diseasechronic diseasesmetabolismdiabetes mellitusliver physiologyliver diseasephysiologytype 2hepatologystiffness progressiondiabetes researchdiabetic medicinemedicinehealth sciencesdiabetesdiabetes therapies

Prediagnostic Plasma Metabolites Are Associated With Incident Hepatocellular Carcinoma: A Prospective Analysis. Cancer Prevention Research (2025)

Robert M. WilechanskyPrasanna K ChallaXijing HanXinwei HuaAlisa K. ManningKathleen E. CoreyRaymond T. ChungWei ZhengAndrew T. ChanTracey G. Simon

public healthmetabolismliver cancerincident hepatocellular carcinomacancer preventionprospective analysispre-diagnostic plasma metaboliteshepatocellular carcinoma

Supplementary Figure S1 From Prediagnostic Plasma Metabolites Are Associated With Incident Hepatocellular Carcinoma: A Prospective Analysis. (2025)

Robert M. WilechanskyPrasanna K. ChallaXijing HanXinwei HuaAlisa K. ManningKathleen E. CoreyRaymond T. ChungWei ZhengAndrew T. ChanTracey G. Simon

pathologyincident hepatocellular carcinomaliver cancerprospective analysisprediagnostic plasma metaboliteshepatocellular carcinoma

Surging Sludge: Intrahepatic Cholangiocarcinoma Mortality on the Rise Worldwide. Hepatology (2025)

pathologysurgical oncologyhepatologydigestive diseaseshepatobiliary tumorsbiliary canceroncologygastrointestinal surgeryrise worldwide

A Natural Language Processing Algorithm Accurately Classifies Steatotic Liver Disease Pathology to Estimate the Risk of Cirrhosis. Hepatology Communications (2024)

Marc S. ShermanPrasanna K. ChallaEric M. PrzybyszewskiRobert M. WilechanskyEugenia N. Uche-AnyaAshley T. OttJessica McGoldrickWolfram GoesslingHamed KhaliliTracey G. Simon

public healthpathologyepidemiologyliver diseasehepatologydisease risk assessmentdisease classificationdisease assessmentnatural language processing

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis. JAMA (2024)

Tracey G. SimonRobert M. WilechanskyStefania StoyanovaAlessandra GrossmanLaura E. DichtelGeorg M. LauerKaren K. MillerYujin HoshidaKathleen E. CoreyRohit LoombaRaymond T. ChungAndrew T. Chan

hepatologyepidemiologypharmacologyliver disease

Controversies in Terlipressin and Transplantation in the United States: How Do We Meld the Two?. Liver Transplantation (2024)

Eric M. PrzybyszewskiRobert M. WilechanskyPaige McLean DiazAndrew S. AllegrettiLisa B. VanWagnerGiuseppe CullaroJosh LevitskyPere GinèsSalvatore PianoSumeet K. AsraniKavish R. Patidar

united stateshepatologymedicineclinical transplantationliver transplantationtransplantation medicine

1
2
3
10 / page

Robert M. Wilechansky

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Digestive Health Center

Division Of Hematology/Medical Oncology

Division of Gastroenterology & Hepatology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

NoneRobert M. Wilechansky is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert M. Wilechansky

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

106 Relationship of Healthy Diet Adherence and Incident Masld and Cirrhosis in a Pooled Analysis of Three Large Prospective Cohorts. Gastrointestinal Endoscopy (2026)

interventional endoscopypublic healthepidemiologychronic diseasesgastrointestinal endoscopydigestive endoscopygastroenterologyhepatologydigestive diseasesfood intolerancehealth sciences

Par for the Course? Comparative Effectiveness of Ppar Agonists in Pbc. Hepatology (2026)

Breaching the Blood–Brain Barrier: Functional Mri Changes in Covert Hepatic Encephalopathy. Hepatology (2025)

Not so Sweet: Faster Liver Stiffness Progression in Masld With Type 2 Diabetes. Hepatology (2025)

Prediagnostic Plasma Metabolites Are Associated With Incident Hepatocellular Carcinoma: A Prospective Analysis. Cancer Prevention Research (2025)

Robert M. WilechanskyPrasanna K ChallaXijing HanXinwei HuaAlisa K. ManningKathleen E. CoreyRaymond T. ChungWei ZhengAndrew T. ChanTracey G. Simon

public healthmetabolismliver cancerincident hepatocellular carcinomacancer preventionprospective analysispre-diagnostic plasma metaboliteshepatocellular carcinoma

Supplementary Figure S1 From Prediagnostic Plasma Metabolites Are Associated With Incident Hepatocellular Carcinoma: A Prospective Analysis. (2025)

Robert M. WilechanskyPrasanna K. ChallaXijing HanXinwei HuaAlisa K. ManningKathleen E. CoreyRaymond T. ChungWei ZhengAndrew T. ChanTracey G. Simon

pathologyincident hepatocellular carcinomaliver cancerprospective analysisprediagnostic plasma metaboliteshepatocellular carcinoma

Surging Sludge: Intrahepatic Cholangiocarcinoma Mortality on the Rise Worldwide. Hepatology (2025)

pathologysurgical oncologyhepatologydigestive diseaseshepatobiliary tumorsbiliary canceroncologygastrointestinal surgeryrise worldwide

A Natural Language Processing Algorithm Accurately Classifies Steatotic Liver Disease Pathology to Estimate the Risk of Cirrhosis. Hepatology Communications (2024)

Marc S. ShermanPrasanna K. ChallaEric M. PrzybyszewskiRobert M. WilechanskyEugenia N. Uche-AnyaAshley T. OttJessica McGoldrickWolfram GoesslingHamed KhaliliTracey G. Simon

public healthpathologyepidemiologyliver diseasehepatologydisease risk assessmentdisease classificationdisease assessmentnatural language processing

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis. JAMA (2024)

Tracey G. SimonRobert M. WilechanskyStefania StoyanovaAlessandra GrossmanLaura E. DichtelGeorg M. LauerKaren K. MillerYujin HoshidaKathleen E. CoreyRohit LoombaRaymond T. ChungAndrew T. Chan

hepatologyepidemiologypharmacologyliver disease

Controversies in Terlipressin and Transplantation in the United States: How Do We Meld the Two?. Liver Transplantation (2024)

Eric M. PrzybyszewskiRobert M. WilechanskyPaige McLean DiazAndrew S. AllegrettiLisa B. VanWagnerGiuseppe CullaroJosh LevitskyPere GinèsSalvatore PianoSumeet K. AsraniKavish R. Patidar

united stateshepatologymedicineclinical transplantationliver transplantationtransplantation medicine

1
2
3
10 / page